Pediatric Updates: Pharmacology: 2020 Current Concepts
Get ready to bolster your peds pharm knowledge! How familiar are you with cannabis hyperemesis syndrome, a newer issue increasing affecting adolescents? How do you tailor primary care for children receiving biologics / immunomodulators? This module covers an extensive list of medication topics to support your practice:
Evidence-based pharmacologic management of constipation
Established and existing pharmacologic management of asthma, seizure disorders, type I and type II diabetes mellitus (including newer insulin delivery systems), rheumatologic diseases, and cannabis hyperemesis syndrome
Mechanism of action for selected anti-epileptic and diabetes medications
Adverse effects of immunomodulatory agents used for inflammatory bowel disease, asthma and rheumatologic disorders; inhaled corticosteroids and beta-agonists for asthma; metformin and insulins for diabetes
Tailoring primary care for children receiving biologics / immunomodulators; monitoring for children receiving these therapies plus others such as methotrexate and inhaled corticosteroids
Recognition and management of common and uncommon, benign and serious cutaneous medication reactions
Legislation and regulatory directives affecting development and approval of pediatric medications, includes discussion of off-label use (historical and current)
7.5 pharmacology contact hours accredited by NAPNAP (0 related to psychopharmacology) (0 related to controlled substances).
Answers are due 150 days from order process date.
What references are included?
11 online PDF articles or web resources (included/provided) to support answering all 39 questions.
Q. Which of the following medications have demonstrated efficacy for treating the nausea and vomiting associated with cannabis hyperemesis syndrome (CHS)? SELECT TWO (2) A. capsaicin cream 0.075% (Qutenza) B. dolasetron (Anzemet) C. haloperidol D. metoclopramide (Reglan) E. scopolamine (Transderm Scōp)